Rigorous screening for atherosclerosis has therefore been proposed for these patients, 2 and there is a need for a noninvasive, simple, and widely available technique for this purpose. High-resolution ultrasonic arterial scanning provides information on arterial atherosclerotic plaques and meets the aforementioned criteria. 3 Carotid intima-media thickness was initially used as a biomarker of atherosclerosis; however, it is now known to be a very weak predictor of cardiovascular risk and is no longer recommended in the American College of Cardiology/American Heart Association guidelines. 3 A few studies used ultrasound to assess the presence of carotid plaques and reported contradictory results on their prevalence in patients with psoriasis. 4 Autopsy studies have observed that the presence of femoral plaque but not carotid plaque is a significant predictor of coronary atherosclerosis and coronary mortality. 5 Our study hypothesis was that ultrasound assessment of atherosclerotic plaques in the femoral artery would be more useful than in the carotid artery in screening for atherosclerosis in patients with psoriasis. We would therefore like to report part of the results of our study of 102 white participants: 51 patients with moderate-to-severe chronic plaque psoriasis (psoriasis area and severity index greater than 10 and body surface area greater than 10%) and 51 healthy control subjects matched 1:1 for age, sex, and body mass index. Patients and controls signed their informed consent before study enrollment. The study protocol was approved by the ethical committee of our institution.
Subjects underwent B-mode and Doppler ultrasound examination with a MyLab 25 Gold ultrasound system (Esaote, Florence, Italy). Ultrasound images were acquired with a linear high-frequency 2-dimensional probe (Esaote LA435). All participants underwent the same vascular ultrasound examination as previously described, 3 examining femoral and carotid arteries bilaterally. Atherosclerotic plaque was defined as a focal structure encroaching at least 0.5 mm into the arterial lumen or having a thickness greater than 50% of the surrounding intima-media thickness. Table I exhibits the anthropometric, clinical, and biochemical data of participants.
To our best knowledge, this is the first study to evaluate the presence of femoral atherosclerotic plaques as a screening test for atherosclerosis in patients with psoriasis. The prevalence of femoral plaques but not carotid plaques was significantly higher in the patients with psoriasis than in age-, sex-, and body mass indexematched controls (P \ .006), whereas the prevalence of femoral plaques among the patients was 2-fold higher than that of carotid plaques (P \ .008) (Fig 1) . According to the present findings, ultrasound study of femoral arteries is more useful than the study of carotid arteries to identify atherosclerosis in patients with psoriasis. To the Editor: Hematopoietic stem cell transplantation (HSCT) is an important treatment option for both malignant and autoimmune conditions, but it requires exposure to profoundly immunosuppressive agents and/or radiation. Unlike in patients who receive a solid organ transplant, restoration of a functional immune system and eventual discontinuation of immunosuppressive medications is the ultimate goal in HSCT. How such treatments may affect the risk of a second or recurrent melanoma in patients who had a melanoma before receiving their transplant is not clear. We searched Duke University Medical Center's historical database of 4528 adult HSCT patients from 1996 to 2017 for patients who had a melanoma before receiving their transplant. One patient whose indication for HSCT was metastatic melanoma was excluded from this study. We included 23 patients (0.5%) with a total of 27 pre-HSCT melanomas (Table I) . A total of 7 patients (30%) underwent allogeneic HSCT, whereas the rest received an autologous transplant. A total of 13 patients (56.5%) were exposed to ionizing radiation (Table II) .
Only 1 patient (4.3%) developed a new melanoma (in situ) 3.1 years after allogeneic HSCT and 32.0 years after the initial melanoma. This patient did not have graft-versus-host disease (GVHD), had only 1 primary melanoma before HSCT, received a nonablative preparative regimen, and was successfully treated with local excision.
There were no recurrences of melanoma. At the median follow-up time of 2.0 years (range 0.02-13.1 years) after HSCT, 5 patients (26.1%) had died (none owing to melanoma). GVHD occurred following HSCT in 42.9% of patients who underwent allogeneic HSCT. This rate was not significantly
